Phase II trial of the antiangiogenic agent IM862 in metastatic renal cell carcinoma
Phase II trial of the antiangiogenic agent IM862 in metastatic renal cell carcinoma
About this item
Full title
Author / Creator
Deplanque, G , Madhusudan, S , Jones, P H , Wellmann, S , Christodoulos, K , Talbot, D C , Ganesan, T S , Blann, A and Harris, A L
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
IM862 is a naturally occurring dipeptide (
L
-glu-
L
-trp) with immunomodulatory and antiangiogenic properties. A significant anticancer activity has been reported recently in AIDS-related Kaposi's sarcoma, a tumour of endothelial cell origin. The high vascularity and responsiveness to immunotherapy of renal cell carcinoma (RCC) makes s...
Alternative Titles
Full title
Phase II trial of the antiangiogenic agent IM862 in metastatic renal cell carcinoma
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2409952
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2409952
Other Identifiers
ISSN
0007-0920
E-ISSN
1532-1827
DOI
10.1038/sj.bjc.6602126
